Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sales & Earnings In Brief

This article was originally published in The Tan Sheet

Executive Summary

Atrium's Garden deal grows sales: The Canadian health and nutrition products manufacturer and marketer continues growing revenues through acquisitions, with sales increasing 8 percent to $81.4 million in its fiscal 2009 third quarter. Atrium Innovations said Nov. 10 the sales growth was "mainly attributable" to its recent acquisition of Garden of Life, its late 2008 acquisition of Nutri-Health and sales of its branded products. The Quebec City-based firm also notes that without the negative impact from foreign currency exchange, revenues would have grown 18 percent. Net income for the July-September period was up 8.3 percent to $13.1 million, or 40 cents per diluted share. The $35 million acquisition of Garden of Life in September gave Atrium direct access to the company's distribution network of nearly 12,000 U.S. health food and specialty retail outlets, including major chains and independent stores (1"The Tan Sheet" Sept. 28, 2009)

You may also be interested in...



Atrium Acquires Garden Of Life, Gains Distribution To Health Food Stores

Atrium Innovations' $35 million acquisition of supplement marketer Garden of Life secures the Canadian firm a strong foothold in the health food store distribution channel and expands its U.S. presence

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103533

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel